| 2.25 -0.13 (-5.46%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.01  |
1-year : | 3.24 |
| Resists | First : | 2.57 |
Second : | 2.77 |
| Pivot price | 2.47  |
|||
| Supports | First : | 2.25 |
Second : | 1.87 |
| MAs | MA(5) : | 2.37 |
MA(20) : | 2.47 |
| MA(100) : | 3.24 |
MA(250) : | 3.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 17.5 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 6.78 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NBP ] has closed above bottom band by 5.3%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.42 - 2.44 | 2.44 - 2.45 |
| Low: | 2.22 - 2.23 | 2.23 - 2.25 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Tue, 28 Apr 2026
Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences - TipRanks
Tue, 28 Apr 2026
NovaBridge Biosciences president buys $577,300 in company shares By Investing.com - Investing.com South Africa
Tue, 28 Apr 2026
NovaBridge Biosciences (NBP) officer buys 230k shares at $2.51 - Stock Titan
Wed, 22 Apr 2026
NovaBridge Biosciences (NBP) names officer Hagler Mark Arnold in Form 3 - Stock Titan
Thu, 09 Apr 2026
NovaBridge's Givastomig Could Drive A Major Re-Rating (NASDAQ:NBP) - Seeking Alpha
Tue, 31 Mar 2026
Bullish NovaBridge Biosciences Insider Buying Worth US$5.09m Yet To Pay Off - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 149 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 4,340 (K) |
| Shares Short P.Month | 5,450 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.9 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -4.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|